Based on high-throughput TCRβ sequencing analysis of samples from the ADJUVANT-CTONG 1104 trial, we found that the diversity of TCR rearrangements was significantly decreased in patients with stage II/III NSCLC with an EGFR mutation, and patients with high TCR diversity had favorable OS. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.